WEEKLY E-NEWS FROM THE NORTH CAROLINA BIOTECHNOLOGY CENTER

IN FOCUS FEATURE

ECU Scientist Seeks End to Pox

FROM OUR WEB SITE

• Rho Signs $38.9M NIH Pact
• FDA OKs Bone Filler
• Hamner, UNC Target Drug Safety
• 5 Bio/Med Firms Boost RTP
• GSK Signs $820M Deal
• NC BioNetwork to Fund Training
• BioDelivery Clears FDA Hurdle

In Focus

ECU Scientist Seeks End to Pox

Rachel Roper, an assistant professor at the Brody School of Medicine at East Carolina University, is performing research to stop the spread of monkeypox around the world. She recently received a $72,497 Biotechnology Research Grant from the North Carolina Biotechnology Center to continue her efforts.

Read more about Rachel's work in this week's In Focus.

 

From Our Web Site

Rho Signs $38.9M NIH Pact
Chapel Hill contract research organization Rho Inc. landed a $38.9 million contract with the National Institutes of Health.

FDA OKs Bone Filler
Technology from Greenville's Encelle, now part of Pioneer Surgical, has been approved to assist bone regrowth.

Hamner, UNC Target Drug Safety
The Hamner Institutes and UNC-Chapel Hill team up in a unique drug-safety research center in RTP. Paul Watkins, M.D, (right) a gastroenterologist and internist and UNC-CH professor of medicine, has been named head the drug safety center.

5 Bio/Med Firms Boost RTP Area
This summer five biotech and/or medical device firms in the Triangle area announced $301 million in investments and more than 425 new jobs.

GSK Signs $820M Deal
GlaxoSmithKline has signed a drug development deal worth as much as $820 million with California company Valeant Pharmaceuticals International.

NC BioNetwork to Fund Training
A prestigious workforce training program funded for the past four years by the U.S. Department of Labor at Forsyth Technical Community College will continue its work as part of NC BioNetwork.

BioDelivery Clears FDA Hurdle
An FDA response letter brings Raleigh's BioDelivery Sciences a step closer to market with BEMA Fentanyl, an oral treatment for pain associated with cancer treatment.

News from Other Sites

East Rowan Graduate Blanchette to Direct Center at N.C. Research Campus
Dr. Christopher Blanchette is director of the Center for Pharmacoeconomic and Outcomes Research at the Lovelace Respiratory Research Institute in New Mexico, which will relocate to Kannapolis next month.
From the Salisbury Post

Gold in the Soil: Native Plants Hold Promise of Big Business for Region
The Bent Creek Center of Innovation for Natural Biotechnology and Integrative Medicine is helping businesses, researchers and universities market products created from the natural herbs grown in North Carolina.
From the Asheville Citizen-Times

Hamner, UNC-CH Teaming to Test Medicines
The Raleigh News and Observer covers the drug safety partnership between the University of North Carolina at Chapel Hill and the Hamner Institutes of Health Sciences.
From the (Raleigh) News & Observer

Community Watch

• Deena Wegner, formerly of Research Triangle Institute-Health Solutions, has joined the Research Triangle Park-based Drug Safety Alliance as vice president of business development and strategy for the pharmaceutical safety and pharmacovigilance organization.

Please send Community Watch items to Jim Shamp.

---

This newsletter was sent Thursday, September 4, 2008. For the latest headlines from North Carolina's biotechnology industry, please visit the news section of our Web site.

Online subscription management is now available. Please respond to this e-mail if you cannot change your preferences online.